Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 59 Cholangiocarcinoma 20 Carcinoma, Renal Cell 16 Biliary Tract Neoplasms 11 Stomach Neoplasms 9 Thyroid Neoplasms 8 Endometrial Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Neoplasms 7 Melanoma 6 Uterine Cervical Neoplasms 5 Thyroid Carcinoma, Anaplastic 5 Neuroendocrine Tumors 5 Carcinoma, Non-Small-Cell Lung 5 Recurrence 4 Ovarian Neoplasms 4 Liver Neoplasms 4 Cirrhosis, Familial, with Pulmonary Hypertension 4 Thyroid Cancer, Papillary 3 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Neoplasm Metastasis 3 Brain Neoplasms 3 Advanced Biliary Tract Cancer 3 Adenocarcinoma, Follicular 3 Vulvar Neoplasms 2 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Thymoma 2 Solid Tumors 2

Interventions

Temozolomide 69 Bevacizumab 40 Radiotherapy 22 Magnetic Resonance Spectroscopy 20 Irinotecan 17 Specimen Handling 10 Carboplatin 10 Carmustine 9 X-Rays 7 Radiation 7 olaparib 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 6 Nivolumab 6 Everolimus 6 Cyclophosphamide 6 Biopsy 6 trametinib 5 Thalidomide 5 Cisplatin 5 pembrolizumab 4 palbociclib 4 fluorodopa F 18 4 erdafitinib 4 dabrafenib 4 Lomustine 4 Etoposide 4 Drug Therapy 4 Doxorubicin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × lenvatinib × Clear all

NCT01137604 2022-09-29

A Study in Subjects With Recurrent Malignant Glioma

Eisai Inc.

Phase 2 Completed

151 enrolled 17 charts

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡